<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03781011</url>
  </required_header>
  <id_info>
    <org_study_id>201712030RIND</org_study_id>
    <nct_id>NCT03781011</nct_id>
  </id_info>
  <brief_title>Oral Carnitine Challenge Test Guides Personalized Therapy for Cardiovascular Disease</brief_title>
  <official_title>Investigation on Clinical Application of Oral Carnitine Challenge Test as a Guidance of Personalized Therapy for Patients With Cardiovascular Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Taiwan University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Taiwan University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators plan to use our recently developed oral carnitine challenge test (OCCT) as
      a tool to exam individual's trimethylamine N-oxide (TMAO) production capacity from their gut
      microbiota. By using data collected by OCCT, the investigators defined subjects as TMAO high
      producer or TMAO low producer and apply low carnitine/choline diet as dietary intervention in
      accordance. After dietary intervention for two months, the investigators repeated OCCT for
      these participants and compare the TMAO production capacity before and after dietary
      intervention.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 19, 2018</start_date>
  <completion_date type="Anticipated">October 19, 2020</completion_date>
  <primary_completion_date type="Anticipated">October 19, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>TMAO production capacity of gut microbiota</measure>
    <time_frame>2 months</time_frame>
    <description>TMAO production capacity measurement by OCCT</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Body Mass Index</measure>
    <time_frame>2 months</time_frame>
    <description>BMI (kg/m^2)</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Platelet aggregation Assay</measure>
    <time_frame>2 months</time_frame>
    <description>Platelet Aggregation ability (% of maximum amplitude)</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Dietary Modification</condition>
  <condition>Cardiovascular Diseases</condition>
  <arm_group>
    <arm_group_label>TMAO high producer</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Low carnitine/choline diet intervention</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TMAO low producer</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Low carnitine/choline diet intervention</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Low carnitine/choline diet habit</intervention_name>
    <description>Patients will received dietary education and supervision by dietician to avoid high carnitine/choline foods including red meat, eggs...etc.</description>
    <arm_group_label>TMAO high producer</arm_group_label>
    <arm_group_label>TMAO low producer</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient with risks of cardiovascular disease (CAD) or CAD patients proved by coronary
             angiography

        Exclusion Criteria:

          -  age &lt; 20, hx of GI surgery, hx of malignancy, antibiotic or probiotic or carnitine
             supplement use within one month, liver cirrhosis, end stage chronic renal disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ming-shiang Wu</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Taiwan University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ming-Shiang Wu, MD PhD</last_name>
    <phone>02-23123456</phone>
    <phone_ext>65043</phone_ext>
    <email>mingshiang@ntu.edu.tw</email>
  </overall_contact>
  <location>
    <facility>
      <name>National Taiwan University Hospital</name>
      <address>
        <city>Taipei</city>
        <zip>100</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ming-Shiang Wu</last_name>
      <phone>886-2-23123456</phone>
      <phone_ext>65043</phone_ext>
      <email>mingshiang@ntu.edu.tw</email>
    </contact>
    <investigator>
      <last_name>Ming-shiang Wu, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>October 2018</verification_date>
  <study_first_submitted>December 10, 2018</study_first_submitted>
  <study_first_submitted_qc>December 17, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">December 19, 2018</study_first_posted>
  <last_update_submitted>December 17, 2018</last_update_submitted>
  <last_update_submitted_qc>December 17, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">December 19, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Gut microbiota</keyword>
  <keyword>Trimethylamine N-oxide</keyword>
  <keyword>Oral carnitine challenge test</keyword>
  <keyword>Cardiovascular disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiovascular Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Choline</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

